Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”. Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”. Takeda was found to have entered into an anticompetitive agreement with generic drugmaker Par Pharma. Credit: Veroniksha/Shutterstock.com. Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement to keep market monopoly of its constipation drug Amitiza (lubiprostone). A jury in the US District Court for the District of Massachusetts found Takeda liable in a pay-for-delay…

Source: Pharmaceutical Technology